For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.


North America is expected to dominate the Phosphoramidite market over the next five years

North America is expected to dominate the Phosphoramidite market over the next five years

The Phosphoramidite Market size is estimated at USD 1.13 billion in 2024 and is expected to reach USD 1.79 billion by 2029, growing at a CAGR of 6.42% in the next five years.

The factors responsible for the growth of the phosphoramidite market include increasing synthetic nucleotide applications in therapeutics, growth in synthetic biology, and therapeutics for different chronic diseases. Also, governments of various nations have been providing research support for synthetic biology because of its extensive applications. 

Furthermore, increasing product launches and approvals are expected to increase the demand for phosphoramidite synthesis, propelling the market growth. 

Click to Continue Reading…

The increasing use of next-generation sequencing technology in several applications, such as biomarker discovery, oncology studies, and personalized medicine, is the key factor driving the market growth. For instance, the fast emergence of next-generation sequencing technology has revolutionized the field of genomics and medical diagnosis and has changed the traditional model of a gene-by-gene approach to syndrome-based panel sequencing, diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). According to the Centers for Disease Control and Prevention (CDC), in 2021, it is projected that more than 60 million people will have their genomes sequenced by 2025 worldwide as countries have taken the initiative to sequence large populations.

Moreover, various companies are developing different ways to utilize phosphoramidite for oligonucleotide synthesis, which are expected to increase their adoption in the pharmaceutical and biotechnology industry.

The increasing number of investments by the government, advancements in research and development about NGS, and the growing prevalence of target diseases are expected to drive market growth in North America. The rising funding by research institutes, companies, and universities for next-generation sequencing is contributing to the growth of the market in the region. For instance, in August 2022, the Department of Health and Human Services announced funding for innovative research and study of structural birth defects with the use of human translational/clinical approaches (genomics, metabolomics, proteomics, etc.) and animal models.

Primopus looks forward to the year ahead

Progress is being made in the multiple interest areas of our phosphoramidites brand, Amideus. We are fairly unique in having a dedicated team working on phosphoramidites for volume application for CDMO purposes. An increasing area of focus is Fmoc Amino Acids where important news will soon be released.

We are meeting the various challenges in all our work with resolute thinking aligned to rigorous SOP. We look forward to working with a growing number of partners across multiple projects in the year ahead.

Primopus at CPHI and Miro Museum

Primopus appreciates art, innovation and impetus

A big thank you to all our clients who attended our booth and our splendid CPHI event at the Picasso/Miro event. The splendid art is an inspiration to all those who appreciate creativity. So it is with our brand Amideus and its focus on phosphoramidites.

You cannot simply think today that one region can supply all the necessary ingredients to make successful pharma. This is why our ‘best of both worlds’ facilities match the strengths of two cultures to produce incredible chemistry of their own.

When we return to our various locations around the world from wonderful Barcelona we will be tired but inspired by the joy of life.

Thanks to all who made our trip productive and memorable in equal measure.

Marcel Velterop
CEO and Member of the Board at Primopus

Primopus Supply Chain News

A CDMO That is Ideally Placed to Meet the Rapidly Changing Pharma Supply Chain Thinking

Driven by a strong geo-political de-risking of overly dependent supply chain arrangements, a drastic rethinking about searching for and developing alternative options is underway in the pharma industry. This is evidenced by several leading companies defining new policies and the separation of activities from select countries.

Primopus has been working diligently to repurpose the pharma Intermediate and API facility it acquired in Switzerland and lays heavy emphasis on sustainable solutions. Our utilities will be net zero carbon from 2028 onwards.
The backward integration to our parent company Deccan Fine Chemicals in India brings massive scale and a huge resource of scientists who have experience in safely scaling-up of complex molecules.

With the launch of our Amideus brand this year, a lot of focus continues to be put on developing, scaling up and supplying of Phosphoramidites (RSMs) to the Oligonucleotide modality which is rapidly gaining interest in the industry.

As the offering broadens with additional critical RSM’s and custom intermediates we are listening to more customers asking about a 2nd independent supply chain option for their strategic API’s. This trend is accelerating and the importance of our Swiss/Indian cultural blend is pivotal in our hybrid value proposition which ultimately improves the reliable supply of essential and complex medicines to global patients.

Contact us today to discuss how we can support your supply chain needs

Amideus from Primopus

Introducing Amideus™, our new Phosphoramidites brand for the Oligonucleotides market

Primopus reaches its first milestone towards becoming one of the largest phosphoramidites manufacturers in the world with Amideus.

Marcel Velterop, Primopus CEO, says “the idea of producing bulk Phosporamidites emerged from a best-of-both-worlds strategy that combines our Swiss installed capacity of up to 250m3 with the massive capacity and broad chemistry base of our parent Deccan Fine Chemicals in India.”

Click here to read more at our new Amideus website

Primopus welcomes 7 new colleagues

Primopus welcomes 7 new colleagues as part of its CDMO expansion plans in Switzerland

Primopus welcomes 7 new colleagues as part of its CDMO expansion plans in Switzerland and wishes everybody a happy, healthy 2023.

During 2023 we expect our team to double in size as we start-up our new pilot plant during Q1 and commercial plant by Q4.

Season’s Greetings to all

As we enter into this festive period, we would like to take this opportunity to wish all of our customers, friends and family all the best for 2023.

2022 has seen us rebrand as Primopus as we embark on the next chapter of the company. 2023 will be equally exciting as we continue to expand our capabilities with new state of the art equipment and look to bring more talent on board.

Primopus VIP event at the Senckenberg natural history museum Frankfurt.

Primopus sets a sustainable course at the Senckenberg Natural History Museum Frankfurt.

Prof Katrin, Director of the Senckenberg Biodiversity and Climate Research Centre gave a very clear message on the importance of biodiversity in achieving a healthy world of the future. Pointing out the interconnectivity of climate, biodiversity and ecology it was clear that multiple species extinction was already happening for a lack of coordinated action worldwide.

Loss of biodiversity has already cost lives, the recent Tsunami in the Indian Ocean highlighted this. More lives were lost in areas where mangroves had been cut.

From a scientific perspective, we now know that the reduction in biodiversity loss can be halted by implementing certain initiatives.

Creating large protected areas of land and ocean including restoring ecosystems with the planting of trees and mangroves.

Changing the mix of agriculture, encouraging organic agriculture with more targeted use of fertiliser. We need to increase yield but understand more fully the knock-on effect of pesticides and if necessary reduce their usage.

A change in diet for northern countries to a more plant-based diet. Three-quarters of world crop production goes to feed animals.  Reducing meat consumption would yield 160 x more land for vegetables which humans can eat directly.

Marcel Velterop CEO of Primopus confirmed that the money Primopus might have spent on a stand at the Frankfurt CPHI had gone into this event to promote a debate on biodiversity and also various initiatives at Deccan to plant trees, preserve wildlife and support renewable energy.

The global challenge of correcting global warming and stopping the extinction of numerous species transcended any corporate or P&L considerations.

Primopus, the newly named pharma CDMO combines an ambitious upcycled facility in Basel, Switzerland with the large intermediates provider Deccan in India.

Marcel confirmed that more improvement was needed by everybody in the industry. It was not so easy to upcycle the facility in Basel, but faced with using another greenfield site it was better for all to upgrade the Basel site rather than build on the greenbelt.

Primopus encourages everybody to embrace ‘exceptional life’ whether it be humans, flora or fauna. By using human ingenuity, we might yet correct some of the damage done to our climate and species biodiversity.

Biodiversity at Primopus

Encouraging Biodiversity

Primopus is organising a VIP event during CPHI Frankfurt, focused on preserving biodiversity and ecosystems at the Senckenberg Museum in Frankfurt. (Watch our brief video presentation below.)

This event will be centred around a talk by Prof. Dr Katrin Bӧhning-Gaese, director of the Senckenberg Biodiversity and Climate Research Center. She won the German Environmental Award in 2021, the largest award for ecological and social commitment in Europe.

The need for the protection of all species on our planet, addressing climate change and embracing human life is an urgent call to action for all of us. We thank Prof. Böhning-Gaese and the Senckenberg for their efforts to promote biodiversity and see this as critically important in our everyday lives at home or in business.

Primopus is developing its CDMO capability in Basel on a site which is being reinvigorated and invested in. It is setting ambitious carbon reduction plans: net zero carbon utilities by 2028. Deccan Fine Chemicals have implemented a wealth of initiatives from tree planting to wildlife habitat preservation.

We have created this brief video presentation that outlines these various initiatives to date and yet there is much more to do. We hope this example will inspire others to follow suit, just as we are inspired by those calling for more positive initiatives. ‘Embracing Exceptional Life’ means we have to value all life on our planet to preserve it for future generations.

Marcel Velterop
CEO Primopus

Basel Net Zero Pledge

“Net Zero Carbon” by 2028 for our Basel, Switzerland CDMO plant

Primopus declares its goal of reaching net zero by working closely with its partner Getec Park.Swiss by 2028.

In line with our new promise and purpose to ‘embrace exceptional life’, we are on the right path to source all our utilities and energy supply to make our production of RSM’s, GMP intermediates and API’s fully net zero.

In phase 2 we will strive to meet the global climate goals and reach net zero for the integrated supply chain latest by 2050.

Deccan invests in Primopus

The Deccan business brings with it a great heritage of sustainability, backward integration into fine-chemical building blocks and large-scale capacity across its multiple sites. Major investments are being made to further enhance the Primopus offering across both sites in Bael, Switzerland and Goa, India

This investment gives Primopus, the ability to secure critical custom-building blocks required for all phases of NCE development we perform for our customers, especially for launch and commercial supply.

Click here to visit the Deccan website